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Introduction: The quadrivalent HPV vaccine is highly effective in primary prevention of anogenital warts (AGWs).
However, there is lack of systematic review in the literature of the epidemiology of AGWs in Sub Saharan Africa (SSA).
Objective: To review the prevalence, incidence and risk factors for AGWs in SSA prior to the introduction of HPV
vaccination programs.
Methods: PubMed/MEDLINE, Africa Index Medicus and HINARI websites were searched for peer reviewed English
language published medical literature on AGWs from January 1, 1984 to June 30, 2012. Relevant additional references
cited in published papers were also evaluated for inclusion. For inclusion, the article had to meet the following criteria
(1) original studies with estimated prevalence and/or incidence rates among men and/or women (2) detailed
description of the study population (3) clinical or self-reported diagnosis of AGWs (4) HPV genotyping of histologically
confirmed AGWs. The final analysis included 40 studies. Data across different studies were synthesized using descriptive
statistics for various subgroups of females and males by geographical area. A meta - analysis of relative risk was
conducted for studies that had data reported by HIV status.
Results: The prevalence rates of clinical AGWs among sex workers and women with sexually transmitted diseases (STDs) or
at high risk of sexually transmitted infection (STIs) range from 3.3% - 10.7% in East, 2.4% - 14.0% in Central and South, and
3.5% - 10.5% in West African regions. Among pregnant women, the prevalence rates range from 0.4% - 3.0% in East, 0.2% -
7.3% in Central and South and 2.9% in West African regions. Among men, the prevalence rates range from 3.5% - 4.5% in
East, 4.8% - 6.0% in Central and South and 4.1% to 7.0% in West African regions. In all regions, the prevalence rates were
significantly higher among HIV+ than HIV- women with an overall summary relative risk of 1.62 (95% CI: 143–1.82).
The incidence rates range from 1.1 – 2.7 per 100 person-years among women and 1.4 per 100 person years among men.
Incidence rate was higher among HIV+ (3.0 per 100 person years) and uncircumcised men (1.7 per 100 person-years) than
circumcised men (1.3 per 100 person-years).
HIV positivity was a risk factor for AGWs among both men and women. Other risk factors in women include presence of
abnormal cervical cytology, co-infection with HPV 52, concurrent bacteria vaginoses and genital ulceration. Among men,
other risk factors include cigarette smoking and lack of circumcision.
Conclusions: AGWs are common among selected populations particularly HIV infected men and women. However, there
is need for population-based studies that will guide policies on effective prevention, treatment and control of AGWs.
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The epidemiology of AGWs in most of SSA is largely
unknown since few studies have been conducted. Stud-
ies from high income countries show that the clinical
burden has been increasing over the years since ap-
proximately 0.5-1.0% of adults below 50 years have
AGWs [1-3].
Caused mainly by low-risk HPV type 6 and 11, AGWs
affect both men and women [1]. They are highly infec-
tious with about 65% of individuals with an infected
partner developing lesions within 3 weeks [4]. The me-
dian time between infection and development of lesions
is about 11–12 months among men [5,6] and about 5–6
months among women [7]. Rarely, AGWs have been as-
sociated with malignant Bushke-Lowenstein malignant
tumors [8]. Their occurrence is strongly linked to HIV
and weakly associated with cigarette smoking [1,4,5]. At
present, the impact of highly active anti-retroviral ther-
apy (HAART) remains unclear [5,6].
Except for Rwanda [9], most countries in SSA are yet
to introduce or scale up HPV vaccination in national
immunization programs. While reduction in disease
burden due to HPV 16/18 may not be evident for de-
cades, vaccination with the quadrivalent HPV vaccine
should result in immediate measurable reduction in
the incidence rate of AGWs. Preliminary results from
the Australian national HPV vaccination program
shows a significant decline in the number of cases of
AGWs among the young vaccinated women and some
herd-immunity effect in young unvaccinated hetero-
sexual men [10]. This review was undertaken to assess
the prevalence, incidence and risk factors for AGWs
before the introduction of HPV vaccination programs
in order to provide a basis for future program evalu-
ation in SSA.
Methods
Identification and eligibility of relevant studies
PubMed/MEDLINE, Africa Index Medicus and HINARI
websites were searched for peer reviewed English lan-
guage published medical literature from January 1, 1984
up to June 30, 2012. The following Medical Subject
Heading (MESH) and search terms were used alone or in
combination “Sub Saharan Africa” AND (“anogenital warts”
OR “venereal warts” OR “condylomata acuminata” OR
“condylomata”) AND “risk factors”. Relevant additional ref-
erences cited in published papers were also evaluated for
inclusion. For inclusion, articles had to meet the following
criteria (1) original studies with clear estimation of preva-
lence and/or incidence rates among men and/or women
(2) detailed description of study population (3) clinical or
self-reported diagnosis of AGWs (4) HPV genotyping of
histologically confirmed AGWs. Studies focusing exclu-
sively on case reports and commentaries were excluded.Data extraction
From each article, the following information was
extracted: first author, publication journal name and year
of publication, country of study population, study sample
type (population- or clinic- based), study design, mean
or median age with range/inter quartile range, whenever
available, sample size, prevalence and/or incidence rate
overall and by HIV status, whenever available, risk fac-
tors and the overall prevalence of HIV, whenever avail-
able. For studies that included populations from
different countries, data was extracted separately for
each country.
Statistical analysis
Data across different studies were synthesized using de-
scriptive statistics for different subgroups of females and
males by geographical areas. A meta- analysis of relative
risk was conducted for studies that had data reported by
HIV status and results presented in a forest plot. In total,
40 studies (39 hospital - and 1 population-based) are in-
cluded in this review.
Results
The prevalence and incidence rates of AGWs in diverse
female and male hospital-based study populations in
East, Central and South, and West African regions is
summarized in Tables 1, 2 and 3. Overall, there is inter-
and intra-region variations in rates depending on the
underlying prevalence rate of HIV-1 infection, study
population and age group studied. While both young
and adult populations were studied, there seems to be
no trend or pattern of prevalence rates by age.
Prevalence rates among women by geographical region
The prevalence rates among women in East, Central and
South, and West African regions are summarized in
Tables 1. The prevalence rates of clinical AGWs among
sex workers and women with STDs or at high risk for
other STIs range from 3.3% - 10.7% in East, 2.4% -
14.0% in Central and South, and 3.5% - 10.5% in West
African regions. Among pregnant women, the preva-
lence rates range from 0.4% - 3.0% in East, 0.2% - 7.3%
in Central and South and 2.9% (single study) in West
African regions.
Prevalence rates of AGWs among men by geographical
region
Eight (8) studies (3 East Africa, 2 Central and South
Africa, 3 West Africa) reported prevalence rates of AGWs
in men (Table 2). The prevalence rate among STD
clinic attendees, men who have sex with men, and men
with symptoms of STDs in Central and South and West
African region range from 4.8% - 12.2% and 2.8% - 4.1%,
Table 1 Studies reporting prevalence of AGWs in women
Author,
Publication year
Country Study design Study population Sample size Mean or Median age
(years, range/IQR1)






Kenya §Cross-sectional Sex workers 196 30.2 (HIV-1+) 31.5 (HIV-1-) 18/196 (9.2) Overall 15/145







520 26 ± 6.8 (14–49) 31/520 (6 .0) 5/520 (1.0)a 29.0 Prevalence of AGWs 5%





Tanzania §Cross-sectional Pregnant women 660 23.4 ± 5.1 (15–44) 20/660 (3.0) 15.0
Riedner et al.,
2003 [14]
Tanzania §Open cohort Female bar workers 600 25.4 39/600 (6.5) Overall 39/408




Tanzania §Cross-sectional Women presenting
with complaints of
genital infections
464 18/464 (3.9) 22.0
Amone-P'Olak,
2005 [16]
Uganda ‡Cross-sectional Formally abducted
teenage girls in
Northern Uganda
123 16.2 ± 2.2 (12–18) 67/123 (54.5)a
Mbizvo et al.,
2005 [17]
Tanzania §Cross –sectional Women seeking
primary health care
services
382 26.7 ± 6.0 8/382 (2.1) 11.5
Msuya et al.,
2006 [18]
Tanzania §Cross-sectional Women seeking
reproductive health
care services












2292 (15–49) 195/2292 (8.5) Prevalence of AGWs
Blantyre – 42/474 (8.9)
Lilongwe – 61/748 (8.2)
Dar es Salaam – 31/428
(7.2) Lusaka – 61/642 (9.5)
Banura et al.,
2008a [21]






1275 20 (12–24) 97/1275 (7.6) 8.6
Banura et al.,
2008b [22]





987 19 (14–24) 61/987 (6.2) 7.3
Urassa et al.,
2008 [23]
Tanzania §Cross-sectional Youth attending an
STI4 clinic
214 20.2 (Females) (13–24)
21.5 (Males) (11–24)




Kenya §Baseline of a
prospective
cohort study
Women at risk for
HIV-infection
361 27 (23–32) 8/361 (2.4) 32.0
Msuya et al.,
2009 [18]
Tanzania §Cross-sectional Pregnant women 2655 24.6 (14–43) 11/2555 (0.4) Overall 2/184



















Table 1 Studies reporting prevalence of AGWs in women (Continued)
Mapingure, et al.,
2000 [25]





Zimbabwe §Cross-sectional Pregnant women
attending STD clinic
175 22.3 23/175 (13.7)
Mason et al.,
1990 [27]
Zimbabwe §Cross-sectional Women attending
STD clinic
100 (15–45) 14/100 (14.0) 1/59 (1.7)a
Kristensen
1990 [28]
Malawi §Cross sectional Adult women with
symptoms of STIs






§Cross-sectional Female sex workers 1233 30/1233 (2.4) Overall 21/431
(5.0) HIV + 8/802 (1.0) HIV-
35.0
Le Bacq et al.,
1993 [30]
Zimbabwe §Cross-sectional New STD clinic
attendees
146 19/146 (13.0) 69.0
Maher et al.,
1995 [31]
Malawi §Cross-sectional Female patients in
general medical care






Pregnant women 1990 – 6603 HIV + 1502
HIV- 5101 1993 – 2161
HIV + 694 HIV- 1457
1995 – 808 HIV + 808
HIV- 701
1990 1993 1995 Overall 4.8






Zambia §Cross-sectional Pregnant women 3160 25 ± 5.3 (14–43) 203/3160 (6.2)
Mbizvo et al.,
2005 [17]
Zimbabwe §Cross –sectional Women recruited
from primary health
care centers
386 26.5 ± 6.8 13/386 (3.4) 29.3
Kurewa et al.,
2010 [34]
Zimbabwe §Cross-sectional Pregnant women 691 24.2 ± 5.1 48/691 (7.0) 50 /691 (7.3)a 25.6
Mapingure et al.,
2010 [26]
Zimbabwe §Cross-sectional Pregnant women 691 24.2 ± 5.1 50/691 (7.3) 33/691 (4.8)b 25.6
Menendez et al.,
2010 [35]
Mozambique §Cross- sectional Women attending
ANC and FP6 clinics
and community





Nigeria §Cross-sectional STD clinic attendees 116 12/116 (10.5)
Ghys et al.,
1995 [37]
Ivory Cost §Cross sectional Female sexual
workers
1209 105/1209 (8.7) Overall 79/567








645 25.3 ± 2.9 (15–41) 19/645 (2.9)
Okesola et al.,
2000 [39]
Nigeria §Cross-sectional Patients attending
an STD clinic


















Table 1 Studies reporting prevalence of AGWs in women (Continued)
Bakare et al.,
2002 [40]






Ghana §Cross-sectional Women attending
gynecological clinic
75 33.3 ± 9.2 (19–57) 4/75 (5.3)a
Sagay et al.,
2009 [42]
Nigeria §Cross-sectional Female sex workers 374 27.8 ± 6.7 (16–63) 17/374 (4.5) Prevalence of AGWs 5/81 (6.1%)




Nigeria §Cross- sectional Patients with genital
ulcer disease
699 369/699 (52.8) Overall 285/506
(56.4) HIV + 84/193 (43.6) HIV –










765 28 (15–54) 27/765 (3.5) Overall 19/273
(7.0) HIV −1 + 8/492 (1.6) HIV -
34.9 HIV-1
0.7 HIV-1 &2
No prevalent AGWs among
women on HAART
a self-reported prevalence; b self-reported prevalence for the last 12 months; c self-reported prevalence among commercial sexual workers; 1Inter quartile range; 2Anogenital warts; 3Sexually transmitted disease;


















Table 2 Studies reporting AGWs in men
Author, year Country Study design Study population Sample
size
Mean or Median age
(years, range/IQR1)
Prevalence of AGWs2 (%) Prevalence of HIV-1% Comments
East Africa
Grijsen et al., 2008 [24] Kenya §Baseline of a prospective
cohort study
Men at high-risk for HIV
infection
536 27 (24–33) 9/500 (1.8) 21.0




2168 20 (19–28) 12/2168 (0.6) Overall 10/1089
(0.9) HIV + 2/1079 ( 0.2) HIV-
Tobian et al., 2012 [46] Uganda †Cross-sectional Heterosexual men 1399 15-49 23/1399 (1.6)a Overall 16/421
(3.8)a HIV + 7/978 (0.7)a HIV –
Central and South Africa
Le Bacq et al., 1993 [31] Zimbabwe §Cross-sectional New STD clinic attendees 319 39/319 (12.2) 61.0
Maher et al. 1995 [32] Malawi §Cross-sectional In-patient male patients in
general medical care
62 39 (20–90) 3/62 (4.8)
Machekano et al., 2000 [47] Zimbabwe §Baseline of prospective
cohort study
Male factory workers who
reported symptoms of STDs
374 22/374 (6.0) 20
Müller et al., 2010 [48] South Africa §Cross-sectional Heterosexual men attending
sexual health services
214 29.8 ± 7.5 108/214 (50.5) 49.5
West Africa
Okesola et al., 2000 [40] Nigeria §Cross-sectional STD2 clinic attendees 1,373 17-74 4.1
Wade et al., 2005 [49] Senegal §Cross sectional Men who have sex with men 463 18-52 13/463 (2.8) 18.1 21.5% Overall 0.5%

























Table 3 Studies reporting incidence rates of AGWs in men and women
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region range from 0.6 -1.8 percent.
Prevalence rates by HIV status
The prevalence rates of AGWs were significantly higher
among HIV+ than HIV- women in all regions with an
overall summary relative risk of 1.62 (95% CI: 1.43–1.82)
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Figure 1 Relative Risk of AGWs among women with known HIV seroprevalence rates were higher among HIV+ than HIV-
men (Table 2).
Incidence rates of AGWs among men and women
Only 3 studies (2 among females and 1 among males)
reported incidence rates of AGWs (Table 3). The inci-
dence rates range from 1.1 – 2.7 per 100 person-years
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status.
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cised (1.7 per 100 person-years) than circumcised men
(1.3 per 100 person-years) [44].
HPV 6 and/or 11 in AGWs
Only 3 studies reported the prevalence of HPV 6 and/or
11 in biopsy specimens or swabs taken from AGWs.
HPV 11 was detected in 100% vulval-vaginal wart speci-
mens obtained from 9 prepubescent South African girls
[52]. HPV 6 and/or 11 was detected in 96.3% of 108
genital swabs taken from heterosexual men with AGWs
attending sexual health clinics in South Africa [48]. Among
74 specimens taken from penile warts of HIV+ men in
South Africa, HPV 6 was detected in 42.5%, HPV 11 in
32.9% and HPV 6/11 in 68.5% [53].
Risk factors for AGWs
Only 2 studies (one among women and another among
men) reported on risk factors for AGWs. Among
women, the risk of prevalent AGWs was 5 times higher
among HIV-1+ than HIV-1- women and 3 times higher
among women who smoked cigarettes than those who
did not. Among HIV-1+ women with low CD4+ count
(≤ 200 cells/μL), the risk of incident AGWs was elevated
20 fold, and 6fold for women with CD4+ count >200
cells/μL. Other risk factors for incident AGWs in
women include detection of HPV 6, concurrent bacterial
vaginoses, genital ulceration, presence of abnormal cer-
vical cytology and the detection of cervical HPV 52 [44].
Lack of circumcision and HIV infection were risk factors
for AGWs in men [45].
Discussion
To the best of our knowledge this is the first systematic
review of the epidemiology of AGWs in SSA. The litera-
ture suggests that AGWs are prevalent among both men
and women populations seeking care in their respective
health care systems. The fewer studies among men is
not surprising given that women generally have more
frequent contact with the health care system than men.
Although there is no marked difference between regions,
absence of a standardized protocol for diagnosis might
have contributed to the observed variations across stud-
ies within the same region. Overall, the prevalence rates
were higher than those reported from retrospective ad-
ministrative databases or medical chart reviews in high
income countries possibly because of underlying HIV in-
fection in several studies [54].
Consistent with published studies, the risk for AGWs was
higher for HIV+ than HIV- men and women [55]. HIV+
women had almost 2 fold risk for HPV infection than
HIV-women. While some AGWs may have been a result of
new infections, recrudescence of existing HPV infection has
been reported among sexually inactive HIV+ women [56].Impaired CD4+ T-lymphocyte response and other forms of
immune dysfunction may be responsible for altering the nat-
ural history of HPV infection among HIV infected individ-
uals [57]. The use of highly active anti-retroviral therapy has
been shown to reduce the risk of opportunistic malignancies
such as Kaposi sarcoma among HIV+ individuals [58], how-
ever, their impact on AGWs remains unclear [55,57,59]. On
the other hand consistent use of male condoms appears to
reduce the risk by 60-70% [60].
Consistent with other studies, HPV 6 and 11 alone or
in combination were detected in the few studies that ex-
amined HPV genotypes in AGWs specimens albeit small
sample sizes. However, the contribution of HPV 11 to
the development of AGWs remains unclear [4,7]. The
concurrent detection of HPV 52 with HPV 6 was not
surprising as co-infection with high risk HPV types has
been reported in 20-50% of AGWs [61,62].
In the absence of a clinical test to establish sub clinical
HPV 6 and 11 infections, identification of risk factors
for acquisition of AGWs independent of other STDs is
complex. Consistent with other studies, low CD4+ cell
count (≤ 200 cells/μL) and abnormal cervical and anal
dysplasias are risk factors for AGWs in HIV+ women and
men, respectively [63,64]. Other risk factors for AGWs in
women identified in this review included co-infection with
HPV 52, and concurrent bacteria vaginoses [65]. In men,
anal HPV infection and related dysplasias [39] and lack of
circumcision [45] were additional risk factors.
Although AGWs are not life threatening, they cause
significant psychological distress and are refractory to
conventional therapies, hence the need for prevention
[4,66]. The quadrivalent HPV vaccine, correct and con-
sistent condom use and limiting the number of sexual
partners are some of the prevention options available to
reduce the risk of contracting AGWs.
It is important to note that there are limitations to this
study. This review focused only on peer reviewed English
language articles published from a few SSA countries,
which limits generalization of the findings. Secondly, most
studies were conducted in hospital-based study popula-
tions, which would favor higher rates than in the general
population. Thirdly, the rates should be interpreted with
caution because of the differences in study populations
and age group studied. While some studies included all
adults [31,39], others focused on narrow age ranges of
specific populations like young people and pregnant
women [23,25] that could have resulted in the observed
high rates. Nevertheless, the review provides vital baseline
data against which the impact of HPV vaccination could
be evaluated in future.
Conclusions
AGWs are common among selected populations par-
ticularly HIV+men and women. However, there is need
Banura et al. Infectious Agents and Cancer 2013, 8:27 Page 9 of 10
http://www.infectagentscancer.com/content/8/1/27for population-based studies on AGWs that will guide
policies on effective prevention, treatment and control
services.
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